Neurocrine Biosciences (NBIX)
(Real Time Quote from BATS)
$146.08 USD
+1.95 (1.35%)
Updated Aug 8, 2024 12:00 PM ET
3-Hold of 5 3
D Value B Growth B Momentum B VGM
Brokerage Reports
Neurocrine Biosciences, Inc. [NBIX]
Reports for Purchase
Showing records 261 - 280 ( 312 total )
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
KINECT 2 Gives Back More Than KINECT 1 Took Away
Provider: Roth Capital Partners, Inc.
Analyst: HAZLETT R
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Initiating on US Biotechnology Sector
Provider: Nomura
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Transferring Coverage and Placing Under Review
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
1Q13 - KINECT and KINECT-II Data Releases in 2H13 Are The Focus
Provider: Roth Capital Partners, Inc.
Analyst: JEN Y
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Former Announcement of the Start of Elagolix in UF Phase IIb Study
Provider: Roth Capital Partners, Inc.
Analyst: JEN Y